Mendelian randomization to establish the causality of uric acid with diabetic nephropathy in type 1 diabetics

Ambreen Gul; Antonia Harford; Philip Zager

doi:10.1016/j.kint.2016.12.035

Mendelian randomization to establish the causality of uric acid with diabetic nephropathy in type 1 diabetics

Kidney Int. 2017 May;91(5):1005-1007. doi: 10.1016/j.kint.2016.12.035.

Authors

Ambreen Gul¹, Antonia Harford², Philip Zager³

Affiliations

¹ Dialysis Clinic, Inc., Albuquerque, New Mexico, USA.
² University of New Mexico, Albuquerque, New Mexico, USA.
³ Dialysis Clinic, Inc., Albuquerque, New Mexico, USA; University of New Mexico, Albuquerque, New Mexico, USA. Electronic address: [email protected].

PMID: 28407875
DOI: 10.1016/j.kint.2016.12.035

Abstract

Previous studies have demonstrated an association of serum uric acid with kidney disease. However, it is unknown whether this relationship is causal. Mendelian randomization takes advantage of allele randomization at birth to assess causation. Using this technique Ahola et al. found strong evidence against causation in Finnish Caucasians with type 1 diabetes mellitus. However, replication in other populations is needed to further assess a potential causal role for hyperuricemia in kidney disease.

Publication types

Comment

MeSH terms

Diabetes Mellitus, Type 1
Diabetic Nephropathies*
Humans
Hyperuricemia / blood
Random Allocation
Uric Acid / blood*

Substances

Uric Acid